Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP1 | P22413 | 3/20 | 0.63 |
| ▸ | ACHE | P22303 | 1/20 | 0.62 |
| ▸ | BACE1 | P56817 | 1/20 | 0.62 |
| ▸ | AURKA | O14965 | 1/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 15/20 | 0.60 |
| ▸ | PDGFRA | P16234 | 10/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20782841 | 1.00 | ENPP1 (0.63) | ENPP1ACHEBACE1AURKAPDGFRB | |
| SCHEMBL30117255 | 0.96 | ENPP1 (0.69) | ENPP1ACHEBACE1AURKAPDGFRB | |
| SCHEMBL23762233 | 0.96 | ENPP1 (0.69) | ENPP1ACHEBACE1AURKAPDGFRB | |
| SCHEMBL20782843 | 0.87 | ENPP1 (0.67) | ENPP1ACHEBACE1AURKAPDGFRB | |
| SCHEMBL23762459 | 0.87 | ENPP1 (0.70) | ENPP1ACHEBACE1AURKAPDGFRB | |
| SCHEMBL30446746 | 0.87 | ENPP1 (0.67) | ENPP1ACHEBACE1AURKAPDGFRB | |
| SCHEMBL20771006 | 0.87 | ENPP1 (0.69) | ENPP1ACHEBACE1AURKAPDGFRB | |
| SCHEMBL25656163 | 0.85 | ENPP1 (0.54) | ENPP1ACHEBACE1AURKAPDGFRB | |
| SCHEMBL20782684 | 0.85 | DRD2 (0.58) | ENPP1ACHEBACE1AURKAPDGFRB | |
| SCHEMBL30446175 | 0.85 | DRD2 (0.58) | ENPP1ACHEBACE1AURKAPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | ENPP1 1/4885ACHE 2363/4885BACE1 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.